Congresses and Publications
Congress Materials
Access abstracts, posters, and presentations presented at the following congresses
January 2021
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)
January 2021 (Virtual)
December 2020
European Society of Medical Oncology Immuno-Oncology (ESMO-IO)
European Society of Medical Oncology Immuno-Oncology (ESMO-IO)
December 2020 (Virtual)
December 2020
American Society of Hematology (ASH)
American Society of Hematology (ASH)
December 2020 (Virtual)
Posters
A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation
Earlier use of zanubrutinib monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with greater efficacy: A pooled analysis from 3 studies
Efficacy and safety of zanubrutinib in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Follow-up results from Arm C of the SEQUOIA (BGB-3111-304) trial
Phase 2 study of zanubrutinib in patients with relapsed/refractory B-cell malignancies intolerant to ibrutinib/acalabrutinib
Safety and efficacy of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with Waldenström macroglobulinemia from a Phase 2 trial
Tumor microenvironment associated with complete response to tislelizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma reveals a potentially different mechanism of action
Zanubrutinib in combination with venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) trial
Abstracts
A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation
Earlier use of zanubrutinib monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with greater efficacy: A pooled analysis from 3 studies
Efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: Initial results of the MAGNOLIA (BGB-3111-214) trial
Efficacy and safety of zanubrutinib in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Follow-up results from Arm C of the SEQUOIA (BGB-3111-304) trial
Phase 2 study of zanubrutinib in patients with relapsed/refractory B-cell malignancies intolerant to ibrutinib/acalabrutinib
Safety and efficacy of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with Waldenström macroglobulinemia from a Phase 2 trial
Tumor microenvironment associated with complete response to tislelizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma reveals a potentially different mechanism of action
Zanubrutinib in combination with venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) trial
November 2020
Society for Neuro - Oncology (SNO)
Society for Neuro - Oncology (SNO)
November 2020 (Virtual)
November 2020
International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)
November 2020 (Virtual)
Posters
A systematic literature review of pharmacoeconomic evaluations for chronic lymphocytic leukemia in Europe
Budget impact analysis of zanubrutinib for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy from the payer perspective in the United States
Healthcare costs and resource utilization associated with PARP Inhibitors in ovarian cancer patients initially treated with platinum-based therapy
Use of PD-1/PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US
Abstracts
A systematic literature review of pharmacoeconomic evaluations for chronic lymphocytic leukemia in Europe
Budget impact analysis of zanubrutinib for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy from the payer perspective in the United States
Healthcare costs and resource utilization associated with PARP inhibitors in ovarian cancer patients initially treated with platinum-based therapy
Use of PD-1/PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US
November 2020
Society for Immunotherapy of Cancer (SITC)
Society for Immunotherapy of Cancer (SITC)
November 2020 (Virtual)
Posters
Association between programmed death-ligand 1 expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma
Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune-hot non-responders with non-small cell lung cancer treated with tislelizumab
T-cell-, MHC I-, and tumor-related gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1-high urothelial carcinoma
Tumor-immune signatures associated with response or resistance to tislelizumab (anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
Abstracts
Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune hot non-responders with non-small cell lung cancer (NSCLC) treated with tislelizumab
T-cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
Tumor-immune signatures associated with response or resistance to tislelizumab (anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
Most Recent Publications
Your ability to access these articles may depend on your or your institution's subscriptions to the journals.
Search Publications and Congress Materials
This website houses a database of publications and congress materials from medical congresses around the world. Use our search engine below to access information pertinent to your search needs.
Clear All
Publications
Your ability to access these articles may depend on your or your institution's subscriptions to the journals.
Publication Name
Author
Year
Disease State
Molecule
Publication Title - [[ publication.Title ]] Author - [[ publication.Author ]] Year - [[ publication.Year ]] Disease State - [[ publication.Indication.join(', ') ]] Molecule - [[ publication.Molecule.join(', ') ]]Loading publications, please wait... No publications found.
Congresses
Material Type and Title
Congress
Year
Disease State
Molecule
[[ type.type ]]
Congress - [[ document.congressName ]] Year - [[ document.year ]] Disease State - [[ document.indications.join(', ') ]] Molecule - [[ document.molecules.join(', ') ]]
Loading congresses, please wait... No congresses found.
BeiGene, Ltd. maintains the site for your personal information, education, and communication. Please feel free to browse the site. You may not, however, distribute, modify, transmit, reuse, repost or use the content of the site for public or commercial purposes, including the text and images, without BeiGene’s written permission.
This is an online medical resource for scientific and clinical information. BeiGene makes no representation that the information in this site is appropriate for every country or region. If you choose to access this site, you are responsible for compliance with applicable local laws.
